Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Bioscience I. 2017 Ltd F2 sold 29,631 shares of the business’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $13.00, for a total transaction of $385,203.00. Following the transaction, the insider now owns 537,392 shares of the company’s stock, valued at approximately $6,986,096. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
NASDAQ CGEM traded up $0.59 during trading hours on Thursday, hitting $13.32. The company had a trading volume of 288,158 shares, compared to its average volume of 401,262. Cullinan Oncology, Inc. has a 1-year low of $7.30 and a 1-year high of $30.33. The company has a market cap of $596.51 million, a PE ratio of -7.53 and a beta of 0.17. The business has a 50 day moving average of $11.14 and a 200-day moving average of $12.93.
Cullinan Oncology (NASDAQ:CGEM – Get Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.34. On average, sell-side analysts predict that Cullinan Oncology, Inc. will post 3.39 earnings per share for the current year.
Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Cullinan Oncology in a research note on Tuesday, May 17th.
About Cullinan Oncology (Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.